Methods for dna-depending targeting of a cell permeant antibody

Abstract

The invention provides methods for selective targeting of live cells, which have undergone or are undergoing radiation or chemotherapy, at a site of interest with a cell-penetrating polypeptide. In one embodiment of the invention, the method comprises contacting the live cells with a cell-penetrating polypeptide comprising cell-penetrating determinants so that the cell-penetrating polypeptide binds extracellular DNA near or around the live cells so as to form a complex or association therewith such that the complex or associated polypeptide-DNA so bound bind the live cells and penetrates the live cells thereby selectively targeting live cells at a site of interest with a cell-penetrating polypeptide.

1 .- 96 . (canceled) 
     
     
         97 . A method for inhibiting tumor cells associated with ischemia, cellular/tissue necrosis or cellular/tissue apoptosis in vivo, by selective targeting of the tumor cells with a cell-penetrating polypeptide, comprising administering the cell-penetrating polypeptide to a subject in need thereof, wherein the cell-penetrating polypeptide is a 3E10 antibody or a fragment thereof. 
     
     
         98 . The method of  claim 97 , wherein the fragment is a single chain Fv (scFv) fragment of mAb 3E10 antibody. 
     
     
         99 . (canceled) 
     
     
         100 . The method of  claim 98 , wherein the 3E10 scFv is formulated in a pharmaceutically acceptable composition. 
     
     
         101 . The method of  claim 100 , wherein the composition is administered to a subject in need thereof by injection. 
     
     
         102 . The method of  claim 101 , wherein the injection of the 3E10 scFv results in localization of the 3E10 scFv to tumor cell nuclei. 
     
     
         103 . The method of  claim 102 , wherein the 3E10 scFv is detectable by immunohistochemistry (IHC) in tumor cell nuclei for up to 24 hours after injection. 
     
     
         104 . The method of  claim 101 , wherein the 3E10 scFv does not localize in major organs to the extent that the 3E10 scFv localizes in tumor cell nuclei. 
     
     
         105 . The method of  claim 104 , wherein the major organs comprise one or more of heart, kidney, skeletal muscle, and liver. 
     
     
         106 . The method of  claim 97 , wherein the tumor cells are associated with a glioma.